Sanofi, Maxygen Ink Dengue Virus Vaccine Agreement
This article was originally published in The Pink Sheet Daily
Executive Summary
$24.5 million-plus licensing deal complements Sanofi’s vaccine work with Maxygen’s technology and could lead to next-generation dengue vaccine, Sanofi tells “The Pink Sheet” DAILY.